US Bancorp’s Kiniksa Pharmaceuticals KNSA Stock Holding History

US Bancorp’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Sell	913 -467	-34%	-$20.7K	﹤0.01%	2767
2025 Q4	$56.9K	Hold	1,380	–	–	﹤0.01%	2637
2025 Q3	$53.6K	Hold	1,380	–	–	﹤0.01%	2648
2025 Q2	$38.2K	Sell	1,380 -93	-6%	-$2.37K	﹤0.01%	2906
2025 Q1	$32.7K	Buy	+1,473	New	+$30.3K	﹤0.01%	2950
2024 Q2	–	Sell	-116	Closed	-$2.29K	–	4045
2024 Q1	$2.29K	Buy	+116	New	+$2.27K	﹤0.01%	3702
2023 Q2	–	Sell	-32	Closed	-$344	–	4063
2023 Q1	$344	Sell	32 -133	-81%	-$1.75K	﹤0.01%	3988
2022 Q4	$2.47K	Sell	165 -834	-83%	-$12.1K	﹤0.01%	3722
2022 Q3	$13K	Buy	+999	New	+$11.4K	﹤0.01%	3267
2022 Q2	–	Sell	-610	Closed	-$6K	–	4145
2022 Q1	$6K	Buy	+610	New	+$6.46K	﹤0.01%	3551

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

US Bancorp's KNSA Position: Q1 2026 in Review

US Bancorp reduced its Kiniksa Pharmaceuticals (KNSA) stake by 34% in Q1 2026, selling an estimated $20.7K and leaving 913 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

US Bancorp first reported a position in KNSA in Q1 2022 and has held it in 10 quarters since. The position peaked at $56.9K in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

US Bancorp held 913 shares of Kiniksa Pharmaceuticals worth $44K as of Q1 2026.
US Bancorp sold 467 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $20.7K.
Kiniksa Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2767 holding.
US Bancorp first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
US Bancorp's Kiniksa Pharmaceuticals position peaked at $56.9K in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.